Rethinking Biotech: How big, long-term bets are paying off

The Canadian biotech sector is experiencing a transformative shift, driven by rapid advancements in foundational technologies and a significant influx of capital. Dr. Carl Hansen, founder and CEO of AbCellera Biologics, highlights how modern computational and genomic tools have accelerated drug discovery, moving from decade-long timelines to rapid, data-driven solutions. AbCellera’s success stems from its platform-based model, which treats drug discovery as an engineering challenge rather than a traditional, product-focused endeavor. Despite this progress, Canada faces structural hurdles, including regulatory friction in clinical trials and underfunded university technology transfer offices that limit intellectual property retention. To compete globally, Canadian firms must abandon conservative, incremental growth strategies in favor of bold, large-scale visions that attract international investment and foster a more resilient, innovation-led industrial ecosystem.